This decision analytical model uses a web-based application and data from the Surveillance, Epidemiology, and End Results program to quantitatively integrate mortality estimates and to examine the impact of cancer treatment delay among adults with cancer during the coronavirus disease 2019 pandemic.
This meta-analysis examines the use of measurable residual disease as an end point in studies to assess survival outcomes in patients with acute myeloid leukemia.
This cohort study looks at outcomes and prognostic factors associated with overall survival and local control after hypofractionated stereotactic radiotherapy to the resection cavity of patients with brain metastases.
This cohort study develops and validates a pretreatment clinical prognostic stage group system for patients with nonmetastatic prostate cancer.
This randomized clinical trial examines the efficacy of weekly paclitaxel with or without bevacizumab as treatment for relapsed sex cord-stromal tumors and whether the addition of bevacizumab to weekly paclitaxel improves 6-month progression-free rates.
This clinical trial assesses the clinical use of site-specific treatment, including molecularly targeted therapy based on next-generation sequencing results, for Japanese patients with cancer of unknown primary site.
This randomized clinical trial compares overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) vs standard of care.
This stepped-wedge cluster randomized clinical trial assesses the effect of a clinician-directed intervention combining machine learning mortality predictions with behavioral nudges vs usual care on motivating serious illness conversations between clinicians and patients with cancer.
This systematic review with meta-analysis compares the effectiveness of different vascular endothelial growth factor inhibitors, checkpoint inhibitors, or their combinations in patients with advanced hepatocellular carcinoma in the first-line or refractory settings.
This case series evaluates pembrolizumab concentrations and programmed cell death 1 blockade on T cells in cerebrospinal fluid after intravenous administration.
This multicenter cohort study characterizes the spectrum of multisystem immune-related adverse events, their association with survival, and risk factors for development, in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
This cohort study identifies trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia and the association those treatment choices have with health care costs.
This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer.
This cohort study evaluates the national practice patterns of MGMT gene testing and identified potential factors associated with access to testing.
This cohort study examines the association between aspirin use and cholangiocarcinoma in an Asian cohort.
This review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights results from clinical trials exploring these approaches.
A 48-year-old man with a history of rectal adenocarcinoma and multiple lung metastases presents with a 1-cm posterior subglottic lesion of unclear origin found on restaging scans. What is your diagnosis?
This Viewpoint provides an evaluation of partial breast irradiation as an alternative to standard and hypofractionated whole-breast irradiation in terms of its ability to reduce duration of treatment and provide equivalent outcomes, comparable or reduced adverse effects, and cost-effectiveness
This Viewpoint explores whether hospital death rates should still be considered an appropriate quality metric when it comes to the care of patients with cancer.
This Viewpoint discusses calls to deescalate therapy and omit radiation in the setting of pathologic complete response for patients with breast cancer.
This Viewpoint describes 3 issues to be considered before upcoming US Food and Drug Administration reviews of electronic cigarette products.
This essay details the the emotional toll of pediatric cancer from the author’s peronal experiences and uses these details to correct misconceptions many have about patients who die from or survive the disease.